![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 17, 12374-12380, April 28, 2000
,
, and
From the
Department of Biochemistry and Molecular
Biology, Colorado State University, Fort Collins, Colorado 80523 and
the § Department of Biological Chemistry and Molecular
Pharmacology, Harvard Medical School, Boston, Massachusetts 02115
| |
ABSTRACT |
|---|
|
|
|---|
The physiological role of TFIIA was investigated
by analyzing transcription in a yeast strain that contains a
TATA-binding protein (TBP) mutant (N2-1) defective for interacting
with TFIIA. In cells containing N2-1, transcription from a set of
artificial his3 promoters dependent on different activators
is generally reduced by a similar extent, indicating that TFIIA
function is largely nonselective for activators. In addition, TATA
element utilization, a core promoter function, is altered at
his3 promoters dependent on weak activators. Genomic
expression analysis reveals that 3% of the genes are preferentially
affected by a factor of 4 or more. Chimeras of affected promoters
indicate that the sensitivity to the TFIIA-TBP interaction can map
either to the upstream or core promoter region. Unlike wild-type TBP or
TFIIA, the N2-1 derivative does not activate transcription when
artificially recruited to the promoter via a heterologous DNA binding
domain, indicating that TFIIA is important for transcription even in
the absence of an activation domain. Taken together, these results
suggest that TFIIA plays an important role in both
activator-dependent and core promoter functions in
vivo. Further, they suggest that TFIIA function may not be
strictly related to the recruitment of TBP to promoters but may also
involve a step after TBP recruitment.
Initiation of RNA polymerase
(pol)1 II transcription
requires the assembly of a large complex of proteins that must interact at the promoter in a productive manner (1, 2). Formation of this
complex is accelerated by activators that bind to the promoter and aid
in recruitment of the components in the complex. The first step in
promoter recognition is binding of TFIID to the TATA element. TFIID is
a multiprotein complex containing TATA-binding protein (TBP) and
TBP-associated factors (3). TFIIA stabilizes the TBP-TATA interaction
(4-7) by interacting directly with the TBP and DNA flanking the TATA
element (8, 9). TFIIA also counteracts several negative regulators of
transcription that specifically target TBP. It inhibits the abilities
of Mot1 and NC2 to dissociate TBP from the TATA element (10-13), and
it blocks the inhibition of TBP binding to the TATA element by the
N-terminal domain of TBP-associated factor 130 (14). Thus, there are
several mechanisms by which TFIIA functions at core promoters in
vitro.
Although TFIIA is not required for in vitro transcription
using highly purified components, activated transcription is often stimulated by TFIIA. This is in accord with the observations that TFIIA
can interact directly with activation domains in vitro
(15-17) and that TFIIA is required for activator-dependent
stabilization of the TFIID·TATA complex (16, 18-20). A simple model
is that the activator-dependent TFIID·TFIIA complex is
formed rapidly and stably on the TATA element, thereby serving as an
efficient scaffold for the remainder of the initiation complex.
Alternatively, TFIIA could act as a coactivator, conveying information
between the activator and TBP. In this regard, in vitro
cross-linking of an activator to TBP bound at a promoter is inhibited
by TFIIA (21), suggesting that TFIIA is positioned between the
activator and TBP. However, other biochemical experiments suggest that
simple recruitment of the TFIID·TFIIA complex is not sufficient for
activated transcription (22, 23). TFIIA may alter the conformation of TFIID such that either TFIID or the TFIIA·TFIID complex is a target for the remainder of the initiation machinery. It should be noted that
the functional interaction between an activator and TFIIA need not be
direct, and biochemical studies have identified coactivator proteins
that interact with the activator and TFIIA (24). The physiological
relevance of these observations and implied mechanisms remains to be established.
Several studies have addressed the role of TFIIA in vivo,
but the results do not establish whether the functions of TFIIA in vivo are related to the activator, the core promoter, or
both. Previously, we showed that a yeast TBP mutant (termed N2-1)
defective for interacting with TFIIA impairs the response to acidic
activators but does not generally affect pol II transcription (25).
However, human TBP mutants severely defective for interacting with
TFIIA are generally incompetent for transcription in transiently
transfected mammalian cells (26). On the other hand, mutants of the
Toa2 subunit of yeast TFIIA that weaken TFIIA-TBP·TATA complex
formation confer selective transcriptional effects (27). Interpretation of these results is complicated because the various mutations might
differentially affect the quality of the TFIIA-TBP interaction and
because potential functions of TFIIA that are unrelated to interactions
with TBP are not addressed. In complementary experiments, reduction of
intracellular TFIIA levels caused a broad, but quantitatively modest,
effect on transcription (7), but these results were limited by the
partial nature of the TFIIA depletion and the lack of experiments
involving activator-dependent transcription.
In this report, we extend our analysis of the N2-1 derivative of TBP
by systematically examining its ability to respond to a large number of
activators, by determining the regions of promoters that are
responsible for altered transcription in the N2-1 strain, and by
performing artificial recruitment experiments. Our results indicate
that TFIIA plays an important role in both
activator-dependent and core promoter functions in
vivo, and they suggest that TFIIA functions, at least in part, in
a step after TBP is recruited to the promoter.
Analysis of his3 Promoter Derivatives--
To analyze
transcriptional stimulation by different yeast activators, we started
with a set of 13 strains described previously (28) that contain
derivatives of the his3 promoter in which the natural
enhancer region located upstream of the noncanonical (TC) and canonical (TR)
his3 TATA elements is replaced with a specific activator
binding site. After transformation of these 13 strains with a
URA3 centromeric plasmid expressing wild-type TBP, the
chromosomal TBP locus was replaced by a derivative in which the TBP
protein coding sequence was replaced by the LEU2 gene.
Finally, derivatives of these strains expressing wild-type TBP or the
N2-1 derivative as the sole source of TBP (on TRP1 centromeric plasmids) were generated by plasmid shuffling. To analyze
the ability of TBP and the N2-1 derivative to mediate the response to
the various activators, cells were grown under appropriate conditions
for the various activators, exactly as described previously (28).
Levels of his3 transcription were determined by quantitative
S1 analyses using hybridization reactions containing 20-40 µg of RNA
and his3 and ded1 32P-labeled
oligonucleotide probes as described previously (29).
Expression Analysis Using Genome Microarrays--
Yeast strains
MMY101 and MMY102 (generated and kindly provided by Mario Mencia) were
derived from ZMY117 (30) by LEU2 disruption of the genomic
copy of TBP in the presence of wild-type TBP on a URA3
centromeric plasmid. TRP1 centromeric plasmids expressing wild-type TBP (for MMY101) or N2-1 (for MMY102) were introduced into
this background by plasmid shuffling. Cells of each strain were
cultured in synthetic medium at 30 °C to an
A600 of 1, collected by centrifugation, and
frozen in liquid nitrogen. Total cellular RNA was isolated by hot acid
phenol extraction (29), and poly(A)-containing RNA was purified using
Qiagen oligotex resin. Oligo(dT)-primed double-stranded cDNA was
derived from this poly(A)-containing RNA, and 1 µg of the product was
transcribed in vitro to generate internally biotin-labeled
complementary RNA (31). The biotin-labeled RNA probes were fragmented,
hybridized to half a set of Affymetrix yeast gene chip arrays (chips C
and D, representing ~3200 open reading frames from chromosomes IX to
XVI), fluorescently labeled, and analyzed on a Molecular Dynamics
confocal scanner (31).
The results for the two strains were analyzed and compared using
Affymetrix GeneChip software. For the comparison of expression results
from the two strains, the data were normalized by two different
methods: in the first, the overall hybridization intensity of the N2-1
sample was set equal to that of the wild-type sample for a given chip;
and in the second, the data were normalized to set the hybridization
intensities of both samples to the actin open reading frame (present on
both C and D chips) at parity. The two methods of normalization yielded
similar results, although there were minor variations in the fold
change, and thus the rank order, of the open reading frames exhibiting
changed expression. The genome microarray results for several
representative RNAs were confirmed by quantitative S1 nuclease
protection assays.
Transcriptional Analyses of Promoter Chimeras--
Based on the
results of genome-wide analysis of transcription in the N2-1 strain,
four genes were selected for analysis of their promoter sequences:
CTR1 and PUT1, which are down-regulated in the
N2-1 background, and ERG3 and CYC1, which are
up-regulated in the N2-1 strain. All promoter fragments were produced
by polymerase chain reaction using oligonucleotide primers that contain
a restriction site at the 5'-end of the primer (an artificial
BamHI site, which adds 6 base pairs to each promoter between
the upstream and core promoter regions). Upstream promoter fragments
are 750 base pairs in length, and the core promoter regions span from
the distal end of the TATA box to the +7 site relative to the A of the
start codon. The hybrid promoter constructs were cloned in frame with the gene encoding a modified version of green fluorescent protein (GFP,
a gift from Pam Silver). The resulting chimeras were linearized with
EcoRV and integrated at the ura3-52 locus of the
TBP or N2-1 strains used for the genome microarray analysis.
Quantitative S1 nuclease protection assays were performed as described
(29) on RNA harvested from each strain. The sequence of the 55 base GFP probe is
CCGTATGTTGCATCACCTTCACCCTCTCCACTGACAGAAAATTTGTGCCCTAATT, and S1
nuclease digestion of the hybrid between yeast RNA and this probe
yields a product of 50 bases.
Artificial Recruitment Experiments--
LexA fusion constructs
were tested in strain FT4, which contains a LexA operator 45 base pairs
upstream of the his3 TATA element and structural gene (32).
To generate molecules expressing LexA-TBP derivatives, the region
encoding Cyc8 of YCp91-LexA-CYC8 (32) was replaced with the
structural gene of wild-type TBP and the N2-1 derivative. The
resulting molecule contains a 1.5-kilobase fragment of the
ADH promoter driving expression of a hybrid protein consisting of the 202 amino acid coding sequence for LexA, the HA1
epitope, the SV40 nuclear localization signal, and the TBP derivative.
YCp22 (the TRP1 vector) and molecules expressing LexA and
the LexA-TBP derivatives were transformed into strain FT4, and
his3 expression was monitored by spotting 104
cells on plates lacking histidine, containing either 0 or 20 mM aminotriazole, a competitive inhibitor of
his3. LexA-TBP fusions were detected by immunoblot analyses
of 100 µg of whole cell extracts using a polyclonal antibody to LexA
and chemiluminescent detection.
Gal4 fusion constructs were tested in the strain MAV103, which contains
the Gal4 UAS fused to the his3 TATA element and structural gene (33). Polymerase chain reaction was used to amplify the open
reading frames of Toa1 and TBP, and these were cloned into pPC97, which
contains the Gal4 DNA binding domain (residues 1-147) on a CEN,
TRP1-marked plasmid (33). Molecules expressing these Gal4
derivatives were transformed into strain MAV103, and his3 expression was monitored by spotting 104 cells on plates
lacking histidine, containing either 0 or 20 mM aminotriazole.
The TFIIA-TBP Interaction Is Important, but Largely Nonselective,
for Activators to Stimulate Transcription from the his3
Promoter--
In yeast and other eukaryotic cells, core promoters
containing TATA and initiator elements are essentially inactive,
indicating that transcription of essentially all genes requires
activator proteins (34, 35). Previously, we showed that the N2-1
derivative of TBP was defective for transcription of genes responding
to three different acidic activators, Gal4, Gcn4, and Ace1, and was defective in vitro for interaction with TFIIA (25). The
growth and transcriptional phenotypes conferred by N2-1, but not by
other TBP mutants, were suppressed by fusion to the Toa2 subunit of TFIIA, demonstrating that the defective TFIIA-TBP interaction is
responsible for the phenotypes in vivo (25, 36). Although it
is impossible to exclude the possibility that the N2-1 derivative might have other defects aside from its inability to interact with
TFIIA, such additional defects do not account for the growth and
transcriptional phenotypes. Interestingly, transcription of a number of
other genes appeared unaffected in the N2-1 strain. This suggests that
activators responsible for transcription of the unaffected genes should
function normally in the N2-1 strain.
To test this hypothesis, we analyzed the role of the TFIIA-TBP
interaction in 13 strains, each of which possesses a binding site for a
different activator located upstream of the his3 TATA and
initiator elements (28). These sites include those recognized by acidic
activators or by activators with unclassified activation domains, as
well as a poly(dA·dT) element that stimulates transcription via its
inherent effect on chromatin structure (37). Unexpectedly, in almost
all cases, his3 transcription is lower in the N2-1 strain than in the corresponding strain expressing wild-type TBP (Fig. 1). In the exceptional case of the
activator Ppr1, transcriptional output is unaffected or slightly
enhanced in the N2-1 strain. Thus, most of the activators tested are
unable to support maximal levels of his3 transcription in
the N2-1 strain. Interestingly, the transcriptional defect is
quantitatively similar (2-3-fold) in essentially all cases examined,
indicating that the TFIIA-TBP interaction is largely nonselective for
activator function.
The TFIIA-TBP Interaction Is Important for his3 TATA Element
Utilization--
The his3 promoter contains a noncanonical
TATA-like element (TC) that is responsible for
initiation at the +1 position and a consensus TATA element
(TR) that is responsible for initiation at +13
(28, 38-40). In accord with previous results (28), strains containing
wild-type TBP show a clear pattern of his3 TATA utilization depending on the quality of activator (Fig. 1 and Table
I). Specifically, as defined by the ratio
of +13 to +1 transcripts, weak activators stimulate transcription
predominantly through TC, moderate activators stimulate transcription equally from TC and
TR, and strong activators preferentially
stimulate transcription through TR. This pattern was interpreted in terms of functional saturation of
TC (and other weak TATA elements) at low to
moderate levels of transcriptional stimulation (28).
As the wild-type pattern of his3 TATA utilization is
governed specifically by the core promoter region and not the activator (28), factors that alter this pattern do so by affecting core promoter
function (30, 41-43). In this regard, the corresponding strains
containing the N2-1 derivative display a different pattern of
his3 TATA element utilization (Table I). In promoters
dependent on weak activators, a larger percentage of the total
transcription is driven from TR, producing a +13
to +1 ratio of nearly 1 or greater. A similarly increased preference
for TR and +13 initiation is also observed for
moderate activators, including Ppr1. Importantly, increased utilization
of TR in strains containing N2-1 is observed even though the overall level of transcription is lower; this contrasts
with the situation in wild-type cells where increased TR utilization is associated with an overall
increase in his3 transcription levels (28). Taken together,
these results suggest that TC is saturating at a
lower level of transcription in the N2-1 strain as compared with wild
type strain and that noncanonical TATA elements depend on the TFIIA-TBP
interaction to achieve maximal levels of transcription. Differential
preference of his3 TATA elements is not observed for potent
activators (Gcn4, Ace1, and Gal4), suggesting that a strong activator
can bypass at least part of the defect associated with a defective
TFIIA-TBP interaction. The observation that the N2-1 derivative alters
the wild-type rules of his3 TATA element utilization
provides evidence that TFIIA performs a function at core promoters.
A Defective TFIIA-TBP Interaction Delays the Induction of
Gal4-dependent Activation--
The modest defect in
Gal4-dependent activation (Fig. 1) appears to conflict with
our previous observation (25) that the N2-1 derivative was completely
unable to mediate activation by Gal4. This apparent discrepancy was
resolved by analyzing the kinetics of Gal4-dependent
activation of GAL1 transcription. The TBP-containing strain
achieves maximal levels of activation by 30-60 min, with an increase
in GAL1 RNA observed after only 10 min in galactose (Fig.
2A; data not shown). In
contrast, the N2-1 strain requires 6 h for detectable induction
and 12 h to reach maximum output. Although there is a substantial
growth difference between the TBP and N2-1 strains (doubling times 85 min and 6 h, respectively), the slow induction of GAL1
transcription is not explained simply by the altered growth rates. For
example, at a time corresponding to half a generation (45 min and
3 h, respectively), GAL1 transcription is maximal in
the strain containing wild-type TBP, whereas it is not detectable in
the N2-1 strain. In the previously published experiment, which
involved a different strain background, the doubling time for the N2-1
strain was 10 h, galactose induction was performed for 18 h,
and GAL1 transcription was not detected. However, when the
original strain is cultured for longer times, a slight
Gal4-dependent response is observed at 24 h, and a
response corresponding to 20-30% of the wild-type level is observed
at 72 h (Fig. 2B). Thus, in both the original and
current strain backgrounds, the N2-1 derivative delays the induction
of Gal4-dependent activation but only causes a mild (3-5
fold) defect in the maximal level of GAL1 transcription.
Effect of a Defective TFIIA-TBP Interaction on Genome-wide
Expression Patterns--
To examine the global implications of an
impaired TFIIA-TBP interaction, we compared the pattern of gene
expression of N2-1 and wild-type cells using microarray technology
(44). Analysis of ~3200 genes reveals that 42 (1.3%) are expressed
at least 4-fold higher in the N2-1 strain than in the wild-type strain
and that 47 (1.5%) are expressed at levels at least 4-fold lower in
the N2-1 strain (Table II). If changes
of at least 2-fold are considered, 9% of genes are expressed at higher
levels in the N2-1 strain, and 8% are expressed at lower levels in
the N2-1 strain relative to the strain containing wild-type TBP. This
percentage of genes preferentially affected by at least 2-fold in the
N2-1 strain is comparable to or higher than that caused by mutations
in GCN5 (5% affected), SRB5 (16% affected), and
SWI2 (6% affected) (45). With the exception of increased
expression of several ribosomal protein genes in the N2-1 strain, we
detected no obvious patterns in the genes with changed expression
levels. The wide range and apparent unrelated nature of genes
preferentially affected by the N2-1 mutation are consistent with the
relative lack of activator specificity observed with the modified
his3 promoters.
An important consideration in interpreting these genome-wide expression
results is that equal amounts of wild-type and N2-1 mRNA samples
were analyzed. For this reason, all changes caused by the defective
TFIIA-TBP interaction (either positive or negative) are defined
relative to the significant majority of "unaffected" genes. Overall
changes in RNA levels, such as a possible broad reduction in the slowly
growing N2-1 strain, are effectively normalized out and hence rendered
imperceptible. Thus, we cannot distinguish whether the genes with
changed RNA levels are indeed the only ones affected or whether they
simply represent, within a globally changed background, an RNA
population disproportionately sensitive (or abnormally insensitive) to
a weakened TBP-TFIIA interaction. Finally, as the N2-1 strain is
stable and viable, the transcriptional profile represents not just the
primary effects of a sabotaged TBP-TFIIA interaction, but also all the
secondary consequences that affect cell growth and perhaps even
transcription by RNA polymerases I and III.
Sensitivity to the TFIIA-TBP Interaction Can Reside in Either the
Upstream or the Core Promoter Region--
To localize the dependence
on the TFIIA-TBP interaction to the upstream or core promoter region,
chimeric promoters were created among four genes specifically affected
in the N2-1 strain (Fig. 3).
PUT1 and CTR1 expression levels are decreased in
the N2-1 strain as compared with wild-type TBP, whereas
ERG3 and CYC1 RNA levels are increased (Table II
and Fig. 4). One part of each chimeric promoter was derived from a gene whose expression is increased in the
N2-1 strain, and the other part was derived from a gene whose
expression was decreased. A complete set of reciprocal chimeras and
control promoters with upstream and core regions from the same gene,
were fused to the GFP structural gene and analyzed for transcriptional
activity in wild-type and N2-1 strains. It should be noted that, with
the exception of CYC1, the promoters utilized in this
experiment have not been subjected to detailed analysis; hence,
boundaries between core and upstream regions have been defined by the
position of the likely TATA element.
For PUT1, decreased expression in the N2-1 strain clearly
maps to the upstream region. Both chimeras containing the
PUT1 upstream region show significantly decreased expression
in the N2-1 strain, whereas both chimeras containing the
PUT1 core region show increased transcription characteristic
of the CYC1 and ERG3 genes. The transcriptional properties of these PUT1 chimeras also suggest that the
CYC1 and ERG3 upstream regions are important for
the differential response to N2-1.
In the case of ERG3 and CTR1, the upstream
regions play the predominant role, but they do not completely account
for the differential response to N2-1. Specifically, the
CTR1 upstream-ERG3 core promoter chimera shows a
decrease characteristic of CTR1, but the chimeric promoter
is less affected than the natural promoter. Conversely, the reciprocal
ERG3-CTR1 chimera behaves more similarly to ERG1 than to CTR1, but the chimeric promoter does not show
increased expression in the N2-1 strain (it may even be very slightly
reduced). Lastly, the core region of CYC1 clearly
contributes to the increased transcription in the N2-1 strain, because
the CTR1-CYC1 chimera behaves indistinguishably from the
natural CYC1 gene. Taken together, these results indicate
that the function of both the upstream region and the core promoter can
be sensitive to a defect in the TFIIA-TBP interaction.
The Defective TFIIA-TBP Interaction Cannot Be Overcome by
Artificial Recruitment of TBP to the Promoter--
When wild-type TBP
is tethered to promoters via a DNA binding domain located upstream of a
TATA element, transcriptional activation occurs in the absence of an
activation domain (46-48). Under these artificial recruitment
circumstances, interactions that require the activation domain are
bypassed, and TBP and other general transcription factors can only
perform core promoter functions. Conversely, LexA-TBP derivatives that
fail to activate transcription upon artificial recruitment are
defective in a core promoter function. By this criterion, the N2-1
derivative is defective in a core promoter function, because LexA-N2-1
does not activate transcription when artificially recruited to a
promoter (Fig. 5A). LexA-N2-1 is expressed at a level equivalent to that of LexA-TBP (Fig.
5B), and it is capable of supporting cell growth (data not
shown). These results indicate that the TFIIA-TBP interaction plays an important role in core promoter function in vivo.
Recruitment of TFIIA to a Promoter Efficiently Stimulates
Transcription--
In addition to TBP, artificial recruitment of
TBP-associated factors (49-51), TFIIB (50, 52), and various subunits
of the pol II holoenzyme (53-56) results in transcriptional
activation. To examine whether TFIIA stimulates transcription when
artificially recruited to a promoter, we examined the activity of a
hybrid protein comprising the Gal4 DNA binding domain and the Toa1
subunit of TFIIA. As shown in Fig. 6,
Gal4-Toa1 stimulates expression of a Gal4-dependent
promoter to a level comparable to that observed with Gal4-TBP. Although
we have not excluded the possibility of a fortuitous activation surface
on Toa1 (57), this result suggests that tethering TFIIA to a promoter
bypasses the need for activator-mediated recruitment of the pol II
machinery. Although this observation does not necessarily indicate that
TFIIA is a target of natural activators, it suggests that a
hypothetical activator-TFIIA interaction will contribute to the level
of transcriptional activation in vivo.
Transcriptional Defects Conferred by the N2-1 Derivative of TBP
Are Relatively Nonspecific for the Activator--
Our original studies
of the N2-1 derivative indicated that transcription dependent on
strong activators (Gcn4, Ace1, and Gal4) was severely defective,
whereas constitutive expression from a broad range of pol II promoters
was relatively unaffected (25). This led us to hypothesize that the
N2-1 strain would be competent for the response to activators involved
in constitutive transcription. In contrast to this expectation,
analysis of his3 promoters driven by a variety of activators
reveals that N2-1 confers reduced (2-3-fold) levels of transcription
in nearly every case (except Ppr1).
Our results force a revision to our original interpretation of the
N2-1 derivative as being specifically defective in the response to
acidic activators. Instead, the transcriptional defects of the
artificial his3 promoters are relatively nonspecific for the
activator. In addition, microarray analysis indicates that the subset
of genes preferentially affected in the N2-1 strain do not show a
clear pattern suggestive of a response to specific activators. Finally,
the relative lack of activator specificity is consistent with the
observation that transcription of nearly all genes tested is reduced
~2-5-fold upon loss of TFIIA (7).
Why do TFIIA-depleted cells show a broad, but quantitatively modest,
reduction in transcription (7), whereas N2-1 cells appear to display
defects for a small subset of genes? One possibility is that the N2-1
derivative does not completely block the TFIIA-TBP interaction and
hence confers a less severe effect than eliminating TFIIA.
Alternatively, because TFIIA is present at normal levels in the N2-1
strain, it might be recruited to promoters by an alternative mechanism
involving interactions with activators (15, 16), TBP-associated factors
in the TFIID complex (58, 59), or TFIIE (60). Finally, the difference
between N2-1 and TFIIA-depleted cells might be more apparent than
real. A broad decrease in pol II transcription in N2-1 cells might be
obscured (or normalized out) by the fact that equivalent amounts of RNA
from wild-type and mutant cells are assayed even though the cells grow
at different rates. Such a broad pol II defect could easily account for
the slow growth of N2-1 strains, and slowly growing cells also have a
reduced steady-state level of pol I and pol III transcription. In
contrast, TFIIA-depleted cells are analyzed soon after the depletion,
conditions in which indirect growth-dependent effects on
pol I and pol III transcription should not be confounding, and the
broad decrease in pol II transcription can be easily observed.
Role for TFIIA in Core Promoter Functions--
Basal transcription
from a core promoter using purified factors is a concept defined
in vitro. In vivo, core promoters typically have very low
levels of transcription (34), probably because of the repressive
effects of chromatin (35, 61, 62). As such, it is likely that
transcription in vivo represents some form of activated transcription.
Consequently, it is often difficult to determine whether an observed
transcriptional defect in vivo reflects a core promoter
function or an activator-specific function. For example, a mutated TATA
element reduces the level of activator-dependent transcription even though the TATA element is clearly involved in a
core promoter function.
Three lines of evidence demonstrate that TFIIA is important for core
promoter function(s) in vivo. First, the N2-1 strain shows
differential utilization of the his3 TATA elements, with TC (the nonconsensus TATA element) saturating at
a lower level of transcription in comparison to the wild-type strain.
This suggests that, relative to TR (the
canonical TATA element), TC is a weaker element
in the N2-1 strain than in the wild-type strain. As the rules of
his3 TATA utilization are governed specifically by the core
promoter region and not the activator (28), factors that alter these
rules do so by affecting core promoter function (30, 41-43). Second,
the N2-1 derivative does not stimulate transcription when artificially
recruited to promoters. As artificial recruitment represents an
experimental situation in which the normal activation process
(i.e. dependent on activation domains) is completely
bypassed, the defect of N2-1 must reflect a core promoter function.
Third, analysis of chimeric promoters indicates that, in some cases, the core region can contribute to altered expression in the N2-1 strain.
Role for TFIIA in Activator-specific Functions--
There are two
basic ways to interpret the observation that the defect in
activator-dependent his3 transcription in the
N2-1 strain is relatively nonspecific for the activator. In one
interpretation, this defect may be because of the his3 core
promoter rather than the specific activator. In this regard, a
defective core promoter function such as a weakened TBP-TATA
interaction can cause the appearance of a defect in the response to
transcriptional activators (28, 63, 64). In the alternative
explanation, TFIIA could perform a common, but not absolutely required,
function that is related to activators. For example, TFIIA could be a
common target of activators or it could stabilize/alter the
conformation of the direct activator target. In this regard, our
observation that Gal4-Toa1 activates transcription suggests that an
activator-TFIIA contact will contribute to transcriptional activity
in vivo. These two basic explanations are not mutually
exclusive, and they also apply to the related observation that
depletion of TFIIA causes a general, and quantitatively similar,
reduction in pol II transcription, even though individual promoters
differ markedly in their upstream regions and hence activator binding sites.
Despite the difficulties of distinguishing between core and
activator-specific functions in many situations, our analysis of
chimeric promoters provides strong evidence that TFIIA does perform a
function that is related to activators. In most cases tested, altered
expression because of the defective TFIIA-TBP interaction is associated
with the upstream region, not the core promoter. Although we cannot
exclude the possibility that the dependence on the upstream region of
the chimeric promoters is indirect (i.e. by altered
expression of genes encoding proteins that interact with these upstream
regions), these results strongly suggest that TFIIA displays some
degree of specificity with respect to activators. Thus, our analysis of
the N2-1 derivatives provides evidence that TFIIA has both
activator-specific and core promoter functions in vivo.
Evidence That TFIIA Has a Role after Recruitment of TBP to the TATA
Element--
A large body of biochemical evidence suggests that TFIIA
stabilizes the TBP-TATA element interaction and stimulates recruitment of TBP to promoters. Our observation that artificial recruitment of
TFIIA (via the Toa1 subunit) results in transcriptional stimulation is
consistent with a role of TFIIA in TBP recruitment, because transcriptional activity is highly correlated with increased TBP occupancy in vivo (65, 66). However, by analogy with other TBP mutants (36), the observation that artificial recruitment of N2-1
does not bypass the defect in the TFIIA interaction suggests a role for
TFIIA in a post-recruitment step for transcription in vivo.
These results do not exclude a role of TFIIA in recruitment of TBP but
rather suggest an additional function(s) of TFIIA after binding the
TATA element. In accord with such a post-recruitment role, there are
TFIIA mutants that are normal for formation of a TBP·TFIIA·TATA
complex but defective for activated transcription in vitro
(67). This suggests that formation of the stable complex is not
sufficient to achieve activated transcription and that TFIIA is
unlikely to function solely as a bridging factor between the activators
and the general machinery. Although the nature of this post-recruitment
step is unknown, TFIIA can induce conformational changes in TFIID at
the promoter (59, 68), and it can physically interact with TFIIE (60),
which functions late in the transcription process (1, 2). Thus, it is
likely that TFIIA plays multiple roles in the transcriptional process
in vivo.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (33K):
[in a new window]
Fig. 1.
The TFIIA-TBP interaction is important, but
largely nonselective, for activators to stimulate transcription from
the his3 promoter. Stimulation of transcription
by various yeast activators in strains containing either wild-type TBP
(odd numbered lanes) or the TFIIA-defective N2-1 allele
(even numbered lanes). RNA from strains containing
HIS3 promoters with binding sites for the indicated
transcription factors or strains that lack a binding site (none) were
subjected to quantitative S1 analysis; the positions of the
his3 (+1 and +13) and ded1 transcripts are
indicated. As the strengths of the activators vary, the three panels
correspond to different exposures.
Differential usage of the two qualitatively distinct TATA elements

View larger version (78K):
[in a new window]
Fig. 2.
Kinetics of Gal4-dependent
activation. A, RNA was harvested from strains grown
from 0 to 24 h in 2% galactose. Strains (FT4 background)
contained the Gal4 DNA binding element driving expression of the
HIS3 gene with either wild-type (TBP) or the
N2-1 allele. The positions of the his3 (+1 and +13) and
ded1 transcripts are indicated. B, RNA was
harvested galactose from strains (KY320 background) containing either
wild-type (TBP) or the N2-1 allele that were grown in 2%
galactose for 0 to 72 h. The positions of the gal1 and
ded1 transcripts are indicated.
Genes that exhibit altered levels of expression in the N2-1 strain

View larger version (34K):
[in a new window]
Fig. 3.
Generation of chimeric promoters derived from
genes differentially affected by the TFIIA-TBP interaction.
A, diagrams of the CYC1, ERG3,
CTR1, and PUT1 promoters with the upstream
regions (thick boxes), core regions (thin boxes),
putative TATA elements (location defined with respect to the ATG codon
at +1), and transcriptional initiation sites (arrows in
cases where this information is known). The boundary between the
upstream and core regions is an artificially generated BamHI
site, which was used to generate the chimeric promoters. All chimeric
promoters were fused to the GFP structural gene and analyzed by S1
analysis using a probe corresponding to residues +79 to +122.
B, transcriptional properties of the chimeric promoters as
determined from data in Fig. 4. For each chimera, the region that
determines the differential response in the N2-1 strain is indicated.
In the CTR1-ERG3 and ERG3-CTR1 chimeras, both
elements contribute with the upstream region playing a predominant role
in latter case.

View larger version (39K):
[in a new window]
Fig. 4.
Transcriptional analysis of chimeric
promoters. RNAs from strains containing chimeric promoters with
the indicated upstream and core promoter regions (see Fig. 3) were
hybridized to completion with a mixture of oligonucleotide probes for
GFP, DED1, and tryptophan tRNA, and the resulting
products were treated with S1 nuclease. The three transcripts were
analyzed on the same gel, but the autoradiograph was exposed for a
longer time in the case of GFP.

View larger version (69K):
[in a new window]
Fig. 5.
Artificial recruitment assay of LexA-TBP and
LexA-N2-1. A, strains containing LexA-TBP, LexA-N2-1,
LexA, or vector and a promoter with a LexA operator 45 base pairs
upstream of the his3 TATA element and structural gene were
tested for growth on 20 mM aminotriazole (AT).
Plates were photographed after 3 days growth at 30 °C. The degree of
AT resistance is directly related to the level of his3
transcription. B, LexA-TBP and LexA-N2-1 proteins are
produced at similar levels. Immunoblot analyses of 100 µg of whole
cell extract from each of the indicated strains probed with anti-LexA
antibody (a gift from R. Brent). The arrows indicate where
the LexA-TBP fusions and LexA alone migrate.

View larger version (22K):
[in a new window]
Fig. 6.
Transcriptional activation by artificial
recruitment of TFIIA. Strains expressing the Gal4 DNA binding
domain (residues 1-147), Gal4-TBP, and Gal4-Toa1 and containing a
promoter with the Gal4 enhancer fused to the his3 TATA
element and structural gene were tested for growth on 20 mM
aminotriazole (AT). The degree of AT resistance is directly
related to the level of his3 transcription.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank Chris Harrington, Mamatha Mahadev, Gene Tanimoto, and Lisa Wodicka for generous hospitality at Affymetrix and essential help in performing and interpreting the microarray analysis, George Church for access to computers to perform microarray data analysis, Mario Mencia for yeast strains and RNA preparation for the genome-wide analysis, and Roger Brent for LexA antibodies.
| |
FOOTNOTES |
|---|
* This work was supported by Research Grants GM56884 (to L. A. S.) and GM30186 (to K. S.) from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at
http://www.jbc.org) contains gene chip data.
¶ To whom correspondence should be addressed. Tel.: (617) 432-2104; Fax: (617) 432-2529; E-mail: kevin@hms.harvard.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: pol, polymerase; TBP, TATA-binding protein; GFP, green fluorescent protein.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Roeder, R. G. (1996) Trends Biochem. Sci. 21, 327-335[CrossRef][Medline] [Order article via Infotrieve] |
| 2. |
Orphanides, G.,
Lagrange, T.,
and Reinberg, D.
(1996)
Genes Dev.
10,
2657-2683 |
| 3. | Burley, S. K., and Roeder, R. G. (1996) Annu. Rev. Biochem. 65, 769-799[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Buratowski, S., Hahn, S., Guarente, L., and Sharp, P. A. (1989) Cell 56, 549-561[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Lee, D. K.,
Dejong, J.,
Hashimoto, S.,
Horikoshi, M.,
and Roeder, R. G.
(1992)
Mol. Cell. Biol.
12,
5189-5196 |
| 6. |
Imbalzano, A. N.,
Zaret, K. S.,
and Kingston, R. E.
(1994)
J. Biol. Chem.
269,
8280-8286 |
| 7. | Kang, J. J., Auble, D. T., Ranish, J. A., and Hahn, S. (1995) Mol. Cell. Biol. 15, 1234-1243[Abstract] |
| 8. | Geiger, J. H., Hahn, S., Lee, S., and Sigler, P. B. (1996) Science 272, 830-836[Abstract] |
| 9. | Tan, S., Hunziker, Y., Sargent, D. F., and Richmond, T. J. (1996) Nature 381, 127-134[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Auble, D. T.,
Hansen, K. E.,
Mueller, C. G. F.,
Lane, W. S.,
Thorner, J.,
and Hahn, S.
(1994)
Genes Dev.
8,
1920-1934 |
| 11. | Goppelt, A., Stelzer, G., Lottspeich, F., and Meisterernst, M. (1996) EMBO J. 15, 3105-3116[Medline] [Order article via Infotrieve] |
| 12. |
Mermelstein, F.,
Yeung, K.,
Cao, J.,
Inostroza, J. A.,
Erdjument-Bromage, H.,
Eagelson, K.,
Landsman, D.,
Levitt, P.,
Tempst, P.,
and Reinberg, D.
(1996)
Genes Dev.
10,
1033-1048 |
| 13. |
Kim, J.,
Parvin, J. D.,
Shykind, B. M.,
and Sharp, P. A.
(1996)
J. Biol. Chem.
271,
18405-18412 |
| 14. |
Kokubo, T.,
Swanson, M. J.,
Nishikawa, J. I.,
Hinnebusch, A. G.,
and Nakatani, Y.
(1998)
Mol. Cell. Biol.
18,
1003-1012 |
| 15. |
Ozer, J.,
Moore, P. A.,
Bolden, A. H.,
Lee, A.,
Rosen, C. A.,
and Lieberman, P. M.
(1994)
Genes Dev.
8,
2324-2335 |
| 16. | Kobayashi, N., Boyer, T. G., and Berk, A. J. (1995) Mol. Cell. Biol. 15, 6465-6473[Abstract] |
| 17. | Clemens, K. E., Piras, G., Radonovich, M. F., Choi, K. S., Duvall, J. F., DeJong, J., Roeder, R., and Brady, J. N. (1996) Mol. Cell. Biol. 16, 4656-4664[Abstract] |
| 18. |
Lieberman, P. M.,
and Berk, A. J.
(1994)
Genes Dev.
8,
995-1006 |
| 19. |
Damania, B.,
Lieberman, P.,
and Alwine, J. C.
(1998)
Mol. Cell. Biol.
18,
3926-3935 |
| 20. |
Ranish, J. A.,
Yudkovsky, N.,
and Hahn, S.
(1999)
Genes Dev.
13,
49-63 |
| 21. |
Emili, A.,
and Ingles, C. J.
(1995)
J. Biol. Chem.
270,
13674-13680 |
| 22. |
Shykind, B. M.,
Kim, J.,
and Sharp, P. A.
(1995)
Genes Dev.
9,
1354-1365 |
| 23. |
Chi, T.,
and Carey, M.
(1996)
Genes Dev.
10,
2540-2550 |
| 24. | Ge, H., and Roeder, R. G. (1994) Cell 78, 513-523[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Stargell, L. A.,
and Struhl, K.
(1995)
Science
269,
75-78 |
| 26. |
Bryant, G. O.,
Martel, L. S.,
Burley, S. K.,
and Berk, A. J.
(1996)
Genes Dev.
10,
2491-2504 |
| 27. |
Ozer, J.,
Lezina, L. E.,
Ewing, J.,
Audi, S.,
and Lieberman, P. M.
(1998)
Mol. Cell. Biol.
18,
2559-2570 |
| 28. | Iyer, V., and Struhl, K. (1995) Mol. Cell. Biol. 15, 7059-7066[Abstract] |
| 29. |
Iyer, V.,
and Struhl, K.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5208-5212 |
| 30. | Moqtaderi, Z., Keaveney, M., and Struhl, K. (1998) Mol. Cell 2, 675-682[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Wodicka, L., Dong, H., Mittman, M., Ho, M. H., and Lockhart, D. J. (1997) Nature Biotech. 15, 1359-1367[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Tzamarias, D., and Struhl, K. (1994) Nature 369, 758-761[CrossRef][Medline] [Order article via Infotrieve] |
| 33. |
Vidal, M.,
Brachmann, R. K.,
Fattaey, A.,
Harlow, E.,
and Boeke, J. D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10315-10320 |
| 34. | Struhl, K. (1989) Ann. Rev. Biochem. 58, 1051-1077[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Struhl, K. (1999) Cell 98, 1-4[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Stargell, L. A., and Struhl, K. (1996) Mol. Cell. Biol. 16, 4456-4464[Abstract] |
| 37. | Iyer, V., and Struhl, K. (1995) EMBO J. 14, 2570-2579[Medline] [Order article via Infotrieve] |
| 38. |
Struhl, K.
(1986)
Mol. Cell. Biol.
6,
3847-3853 |
| 39. |
Chen, W.,
and Struhl, K.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
2691-2695 |
| 40. |
Mahadevan, S.,
and Struhl, K.
(1990)
Mol. Cell. Biol.
10,
4447-4455 |
| 41. | Collart, M. A., and Struhl, K. (1993) EMBO J. 12, 177-186[Medline] [Order article via Infotrieve] |
| 42. | Collart, M. A. (1996) Mol. Cell. Biol. 16, 6668-6676[Abstract] |
| 43. | Moqtaderi, Z., Bai, Y., Poon, D., Weil, P. A., and Struhl, K. (1996) Nature 382, 188-191 |
| 44. | Lockhart, D. J., Dong, H., Byrne, M. C., Follettie, M. T., Gallo, M. V., Chee, M. S., Mittmann, M., Wang, C., Kobayashi, M., Horton, H., and Brown, E. L. (1996) Nature Biotechnol. 14, 1675-1680[CrossRef][Medline] [Order article via Infotrieve] |
| 45. | Holstege, F. C., Jennings, E. G., Wyrick, J. J., Lee, T. I., Hengartner, C. J., Green, M. R., Golub, T. R., Lander, E. S., and Young, R. A. (1998) Cell 95, 717-728[CrossRef][Medline] [Order article via Infotrieve] |
| 46. | Chatterjee, S., and Struhl, K. (1995) Nature 374, 820-822[CrossRef][Medline] [Order article via Infotrieve] |
| 47. | Klages, N., and Strubin, M. (1995) Nature 374, 822-823[CrossRef][Medline] [Order article via Infotrieve] |
| 48. | Xiao, H., Friesen, J. D., and Lis, J. T. (1995) Mol. Cell. Biol. 15, 5757-5761[Abstract] |
| 49. |
Apone, L. M.,
Virbasius, C. A.,
Reese, J. C.,
and Green, M. R.
(1996)
Genes Dev.
10,
2368-2380 |
| 50. |
Gonzalez-Couto, E.,
Klages, N.,
and Strubin, M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
8036-8041 |
| 51. | Keaveney, M., and Struhl, K. (1998) Mol. Cell 1, 917-924[CrossRef][Medline] [Order article via Infotrieve] |
| 52. | Lee, M., and Struhl, K. (1997) Mol. Cell. Biol. 17, 1336-1345[Abstract] |
| 53. |
Jiang, Y. W.,
and Stillman, D. J.
(1992)
Mol. Cell. Biol.
12,
4503-4514 |
| 54. | Barberis, A., Pearlberg, J., Simkovich, N., Farrell, S., Reinagel, P., Bamdad, C., Sigal, G., and Ptashne, M. (1995) Cell 81, 359-368[CrossRef][Medline] [Order article via Infotrieve] |
| 55. |
Farrell, S.,
Simkovich, N.,
Wu, Y. B.,
Barberis, A.,
and Ptashne, M.
(1996)
Genes Dev.
10,
2359-2367 |
| 56. |
Gaudreau, L.,
Keaveney, M.,
Nevado, J.,
Zaman, Z.,
Bryant, G. O.,
Struhl, K.,
and Ptashne, M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2668-2673 |
| 57. | Li, Y. F., Le Gourierrec, J., Torki, M., Kim, Y. J., Guerineau, F., and Zhou, D. X. (1999) Plant Mol. Biol. 39, 515-525[CrossRef][Medline] [Order article via Infotrieve] |
| 58. | Hansen, S. K., and Tjian, R. (1995) Cell 82, 565-575[CrossRef][Medline] [Order article via Infotrieve] |
| 59. |
Emami, K. H.,
Jain, A.,
and Smale, S. T.
(1997)
Genes Dev.
11,
3007-3019 |
| 60. |
Yokomori, K.,
Verrijzer, C. P.,
and Tjian, R.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
6722-6727 |
| 61. | Felsenfeld, G. (1992) Nature 355, 219-224[CrossRef][Medline] [Order article via Infotrieve] |
| 62. | Paranjape, S. M., Kamakaka, R. T., and Kadonaga, J. T. (1994) Ann. Rev. Biochem. 63, 265-297[CrossRef][Medline] [Order article via Infotrieve] |
| 63. | Arndt, K. M., Ricupero-Hovasse, S., and Winston, F. (1995) EMBO J. 14, 1490-1497[Medline] [Order article via Infotrieve] |
| 64. | Lee, M., and Struhl, K. (1995) Mol. Cell. Biol. 15, 5461-5469[Abstract] |
| 65. | Kuras, L., and Struhl, K. (1999) Nature 389, 609-612 |
| 66. | Li, X.-L., Virbasius, A., Zhu, X., and Green, M. R. (1999) Nature 389, 605-609 |
| 67. |
Ozer, J.,
Bolden, A. H.,
and Lieberman, P. M.
(1996)
J. Biol. Chem.
271,
11182-11190 |
| 68. | Oelgeschlager, T., Chiang, C. M., and Roeder, R. G. (1996) Nature 382, 735-738[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
H. Zhou, S. Spicuglia, J. J.-D. Hsieh, D. J. Mitsiou, T. Hoiby, G. J. C. Veenstra, S. J. Korsmeyer, and H. G. Stunnenberg Uncleaved TFIIA Is a Substrate for Taspase 1 and Active in Transcription. Mol. Cell. Biol., April 1, 2006; 26(7): 2728 - 2735. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gilfillan, G. Stelzer, E. Piaia, M. G. Hofmann, and M. Meisterernst Efficient Binding of NC2{middle dot}TATA-binding Protein to DNA in the Absence of TATA J. Biol. Chem., February 18, 2005; 280(7): 6222 - 6230. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Warfield, J. A. Ranish, and S. Hahn Positive and negative functions of the SAGA complex mediated through interaction of Spt8 with TBP and the N-terminal domain of TFIIA Genes & Dev., May 1, 2004; 18(9): 1022 - 1034. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Kraemer, R. T. Ranallo, R. C. Ogg, and L. A. Stargell TFIIA Interacts with TFIID via Association with TATA-Binding Protein and TAF40 Mol. Cell. Biol., March 1, 2001; 21(5): 1737 - 1746. [Abstract] [Full Text] |
||||